Detection of tsh binding inhibiting antibodies (TBI-ab) and thyroid adenylate cyclase stimulating antibodies (TS-ab) in sera of patients with Graves' disease.
In the sera of patients with Graves' disease have been demonstrated the immunoglobulins able to inhibit the binding of TSH to the human thyroid membrane (TBI-Ab) and the immunoglobulins stimulating the thyroid adenylate cyclase (TS-Ab). The present study was performed in 75 hyperthyroid Graves' patients to ascertain the pathophysiological significance of these immunoglobulins. TS-Ab and TBI-Ab prevalence appeared to be much higher in the untreated and in relapsing patients than in subjects in remission. When the results of TBI-Ab and TS-Ab were compared in each group of patients no correlation was found between the two activities. We conclude that the TBI-Ab and the TS-Ab are the markers of hyperthyroidism in Graves' disease but the two activities are not equivalent and probably reflect a different phenomenon concomitantly produced.
D000262:Adenylyl Cyclases / Q000276:immunology*; D000328:Adult; D001323:Autoantibodies / Q000032:analysis*; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D013961:Thyroid Gland / Q000201:enzymology / Q000276:immunology; D013972:Thyrotropin / Q000276:immunology*
D001323:Autoantibodies; D007074:Immunoglobulin G; D008713:Methimazole; D013972:Thyrotropin; D000262:Adenylyl Cyclases